Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 9, Number 9—September 2003

Dispatch

Fluoroquinolone and Macrolide Treatment Failure in Pneumococcal Pneumonia and Selection of Multidrug-Resistant Isolates

Emilio Pérez-Trallero*†Comments to Author , José M. Marimon*, Luis Iglesias*, and Julián Larruskain*
Author affiliations: *Hospital Donostia, San Sebastián, Spain; †Universidad del País Vasco, San Sebastián, Spain

Main Article

Table 1

In vitro antibiotic susceptibilities determined by agar dilution in Streptococcus pneumoniae isolates

Drug MIC (μg/mL) for each isolate/specimen collected, by date
1st isolate/sputum, 1-26-2002 2nd isolate/sputum, 2-8-2002 3rd isolate/sputum, 2-20-2002 4th isolate/sputum, 2-20-2002 5th isolate/pleural fluid, 02-26-2002
Ciprofloxacin
2
32
16
16
16
Levofloxacin
2
16
16
16
16
Moxifloxacin
1
4
4
4
4
Gemifloxacin
0.06
0.5
0.5
0.5
0.5
Erythromycin (14-m macrolide)
0.25
2
>128
>128
>128
Clarithromycin (14-m macrolide)
0.25
2
>128
>128
>128
Azithromycin (15-m macrolide)
0.5
4
>128
>128
>128
Midekamycin (16-m macrolide)
0.5
4
128
64
16
Clindamycin
0.25
≤0.25
16
16
16
Quinupristin-dalfopristin a
1
32
>32
>32
2
Telithromycin ≤0.12 2 8 16 0.5

a Determined by E-test; m, membered.

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO